Clinical Trials Browser

Phase 2 × Prostatic Neoplasms × SB939 compound × Clear all

NCT01075308 2023-08-04

SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms